The long-term prognosis of<unk>  is unknown, though it appears to have no effect on life expectancy at least up to the fourth decade of life. However, as mentioned previously, movement problems can often be severe enough to confine individuals to a wheelchair at an early age, and both visual acuity and spasticity tend to worsen over time. Epidemiology == First described in 1989,<unk>  has been reported almost exclusively in individuals of Iraqi Jewish origin with only two exceptions, one of whom was a Turkish Kurdish, with the other being of Indian descent. Within the Iraqi Jewish population, the carrier frequency of the founder mutation is about 1/10, with the prevalence of<unk>  itself estimated at anywhere between 1 in 400 and 1 in 10,000.
Costeff syndrome
Bangstad syndrome
Ross' syndrome
Melnick–Needles syndrome
Feingold syndrome
Young–Simpson syndrome
Raymond–Céstan syndrome
Jeavons syndrome